Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02632708
Title Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Agios Pharmaceuticals, Inc.

acute myeloid leukemia


Enasidenib + Etoposide + Mitoxantrone

Cytarabine + Enasidenib

Cytarabine + Idarubicin + Ivosidenib

Cytarabine + Daunorubicin + Enasidenib

Cytarabine + Enasidenib + Idarubicin

Etoposide + Ivosidenib + Mitoxantrone

Cytarabine + Ivosidenib

Cytarabine + Daunorubicin + Ivosidenib

Age Groups: adult | senior
Covered Countries USA | DEU

Additional content available in CKB BOOST